Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RZLT
REZOLUTE, INC.
NASDAQ
$4.62
▼ DOWN 7.23% (-0.36)

KEY STATISTICS

Market Cap$444.87 M
52w High$11.46
52w Low$1.07
Dividend Yield—
Frequency—
P/E-5.63
Volume1.08M
Shares Out.96.29M

COMPANY

LEADERSHIP

Nevan Charles Elam
CHIEF EXECUTIVE
Nevan Charles Elam

COMPENSATION 2026

Salary$610,825
Stock Awards$1,767,204
Incentive Plan Pay$0
All Other Comp.$21,418
Total$2,851,109

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 14, 2013
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
68

PRICE TARGET

Target High$14.00
Target Low$6.00
Target Median$6.00
Target Consensus$8.67

UPCOMING EARNINGS

DateSep 16, 2026
DayWednesday
Rev. Est.—
SEP
16
WED

SPLIT RECORD

DATETYPERATIO
2020-10-13Reverse1:50
2014-05-28Reverse1:6
2014-05-01Reverse1:6

PRICE

$4.62 ▼ DOWN 7.23% (−$0.36)
OVERLAYS
$4.60$4.70$4.80$4.909:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.62

About Rezolute, Inc.

https://www.rezolutebio.com ↗

Rezolute, Inc. is a Redwood City-based biopharmaceutical company developing therapies for metabolic diseases, with lead candidates RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema.

INDUSTRY

Biotechnology

A PRODUCT REZOLUTE, INC. IS KNOWN FOR

Ersodetug (RZ358)
Ersodetug (RZ358)

Ersodetug, Rezolute's lead monoclonal antibody, is in Phase 3 trials for severe hypoglycemia caused by hyperinsulinism, including congenital and tumor-associated forms.

COMPETITORS

COMPETITOR
AMPH COMPARE
MBX COMPARE
VRTX COMPARE
XERS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
74
LISTED HERE
16
RANKED BY POSITION SIZE
VTS.AX
0.00% · 2.7M
XSU.TO
0.01% · 2.0M
SCHA
0.01% · 407.9K
FESM
0.03% · 366.3K
JSML
0.43% · 322.8K
DFAS
0.01% · 319.9K
ZPRR.DE
0.01% · 140.7K
GSSC
0.06% · 125.3K
SBIO
0.23% · 119.2K
BBC
0.75% · 78.4K
XRSU.L
0.01% · 71.6K
AVSC
0.01% · 59.9K
RSSL
0.01% · 37.2K
URTY
0.00% · 3.2K
RESM
0.01% · 156
SC0K.DE
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
84.14%
HOLDERS
182
TOP 12 OF 182 · RANKED BY POSITION SIZE
Federated Hermes, Inc.
16.5M sh · $39.02M
Fmr LLC
12.8M sh · $119.98M
Ra Capital Management, L.P.
9.2M sh · $21.66M
Blackrock, Inc.
6.8M sh · $15.97M
Opaleye Management Inc.
6.3M sh · $19.21M
Balyasny Asset Management L.P.
5.0M sh · $15.4M
Siren, L.L.C.
4.9M sh · $45.78M
Vanguard Group Inc
4.8M sh · $11.3M
Bank Of America Corp /De/
4.3M sh · $10.21M
State Street Corp
4.0M sh · $9.4M
Jennison Associates LLC
3.4M sh · $10.49M
Blackstone Inc.
3.0M sh · $28.42M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
ROBERTS BRIAN KENNETH
Sale · 3.1K shares
2026-07-02
★
DIRECTOR, OFFICER: CEO
Elam Nevan C
Sale · 8.0K shares
2026-07-02
★
OFFICER: CFO
Evans Daron
Sale · 3.1K shares
2026-07-02
★
OFFICER: CFO
Evans Daron
Purchase · 10.0K shares
2026-03-30

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OUTPERFORM 1
MARKET OUTPERFORM 1
6 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY Wedbush OUTPERFORM Maxim Group BUY Citizens MARKET OUTPERFORM HC Wainwright & Co. BUY BTIG BUY

SECTORS PEERS

PEERPRICE
NBTX$41.23COMPARE
TYRA$24.94COMPARE
KURA$12.66COMPARE
MRVI$7.68COMPARE
SVRA$5.26COMPARE
GERN$1.51COMPARE
PRME$3.61COMPARE
EYPT$4.48COMPARE